GVR Report cover Monkeypox Vaccine And Treatment Market Size, Share & Trends Report

Monkeypox Vaccine And Treatment Market Size, Share & Trends Analysis Report By Product (Vaccine, Drugs, Vaccinia Immune Globulin), By Gender, By Route Of Administration, By End-use, By Region, And Segment Forecasts, 2022 - 2030

  • Report ID: GVR-4-68039-981-4
  • Number of Pages: 100
  • Format: Electronic (PDF)
  • Historical Range: 2022 - 2030
  • Industry: Healthcare

Report Overview

The global monkeypox vaccine and treatment market size was valued at USD 85.23 million in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 10.16% from 2022 to 2030. Factors such as the increasing incidence of monkeypox infection across the globe and the rising demand for treatment and prevention methods are anticipated to drive the market. For instance, in July 2022, Bavarian Nordic A/S announced that the company received an additional order for 2.5 million doses of JYNNEOS from the U.S. BARDA. Moreover, a surge in product approvals and increasing government initiatives to support research related to monkeypox infection are expected to fuel market growth. According to the CDC data, as of 8th September 2022, 56,609 cases were reported across the globe with 18 deaths. The U.S. and Europe have the highest number of registered cases. Increasing incidence rate in these regions is encouraging market players to develop novel treatments to manage the burden of disease in their regions.

 U.S. monkeypox vaccine and treatment market size, by product, 2022 - 2030 (USD Million)

The increasing incidence of infection and growing demand for vaccination across the globe are likely to boost the market growth during the forecast period. For instance, the world has reported 56,609 new cases of monkeypox infection till 8 September 2022 and the number is increasing. Moreover, according to the data published by the CDC, the U.S. has administered 461,049 vaccine dosages in the country till 6 September 2022.

Moreover, various government initiatives for the supply, distribution, and availability of vaccines to prevent infection are anticipated to facilitate market growth in the coming years. For instance, in July 2022, the Department of Health and Human Services announced to increase the availability of vaccines by procuring additional 144,000 doses of JYNNEOS vaccine for the management of monkeypox infection. In addition, the Health Resources and Services Administration received an allotment for rapid distribution of JYNNEOS to the Ryan White HIV/AIDS Program (RWHAP) to increase the vaccination rate among the high-risk population.

Furthermore, the government initiatives such as the U.S. Monkeypox Research Priorities to boost R&D and increase awareness among people regarding monkeypox are expected to boost growth. Moreover, the U.S. government along with its international partners are boosting their efforts to promote monkeypox research. Some of the government-supported research activities for infection include conducting clinical and epidemiologic observational modeling and conducting vaccine and therapeutic clinical trials, among others. Such initiatives are expected to increase the demand for vaccination at an exponential rate in the coming years.

In addition, in September 2022, the U.S. FDA announced further steps to boost monkeypox testing capacity and accessibility in response to the current outbreak. Under this initiative, the FDA is expected to recommend EUA requests for monkeypox diagnostic tests and promote diagnosis. Thus, such initiatives are expected to propel the market forward during the forecast period.

The ongoing regulatory approvals and EUA are contributing to market expansion. For instance, in August 2022, the U.S. FDA approved emergency use authorization for JYNNEOS vaccine intradermal injectable for healthcare professionals over 18 years of age and older determined to be at higher risk of monkeypox infection. This approval allows two doses of JYNNEOS by intradermal injection four weeks apart.

In addition, in July 2022, EMA’s human medicines committee recommended an extension of the indication of the smallpox vaccine IMVANEX to protect people from monkeypox infection. IMVANEX has been approved since 2013 but has been considered a useful vaccine because of the similarities between smallpox and monkeypox. Moreover, increasing R&D and usage of the smallpox vaccine as an off-label product for vaccination against monkeypox are expected to drive the market across the globe.

Product Insights

The drugs segment led the market in 2022 with a share of over 70.0%. Increasing patient base of monkeypox disease, increasing usage of antiviral drugs, and high treatment cost for the symptomatic treatment of the disease are some key factors fueling the growth. For instance, in July 2022, the U.K. approved SIGA’s tecovirimat (oral) for the treatment of monkeypox and other indications in adults and children with body weights above 13 kg. The drug also has approval in other European countries for the treatment of monkeypox disease.

The vaccine segment is expected to grow at a significant rate over the forecast period. Factors such as increasing adoption of vaccines for monkeypox infection, rising awareness regarding vaccination, and extensive R&D efforts to develop novel products are expected to support segment growth. Moreover, various government initiatives for making vaccines available are anticipated to fuel segment growth. For instance, in August 2022, the HHS facilitated an agreement between Grand River Aseptic Manufacturing and Bavarian Nordic to establish the first finish and fill line of the JYNNEOS vaccine in the U.S.

Gender Insights

The male segment dominated the market in 2022 with a revenue share of over 90.0%. The higher prevalence of monkeypox among men as compared to women is the major factor driving the segment demand. For instance, according to the CDC, the virus affected almost 13,826 males. Thus, the higher prevalence of infection in men than women is likely to augment segment growth.

Moreover, a higher number of vaccine doses among the male population has increased the segment share. For instance, till 6 September 2022, more than 90% of total JYNNEOS vaccine doses are administered to the male population in the U.S.

End-use Insights

Hospitals captured the largest revenue share of over 75.0% in 2022 and are projected to maintain their position during the projected period. Higher hospitalizations owing to the monkeypox outbreak and increased demand for therapeutic products in hospitals for symptomatic treatment are expected to fuel growth. Moreover, various initiatives undertaken by government bodies such as the American Hospital Association and the Department of Health and Human Services to improve the treatment and continuous monitoring of patients’ health having monkeypox infections are increasing the patient base in the hospital.

The specialty clinics segment is likely to be the fastest-growing segment over the forecast period. The growth of the segment is governed by rising awareness among people about immunization and high infection rates of the virus.

Route Of Administration Insights

In 2022, the oral segment held the largest market share of over 65.0%. The higher demand for oral route therapeutics, ease of administration, and cost-effectiveness of oral products are some of the factors contributing to the segment expansion. Moreover, most common drugs such as tecovirimat and brincidofovir are administered orally.

 Global monkeypox vaccine and treatment market share, by route of administration, 2022 (%)

The injectable segment is projected to grow at a double-digit rate over the forecast period. Increasing demand for vaccines, higher bioavailability of injectable products, rapid onset of action of treatment products, and less possibility of first-pass metabolism in case of intravenous products are some of the factors contributing to the segment growth.

Furthermore, the injectable route helps to optimize the immunogenicity of the vaccine and reduce adverse reactions at the site of injection. An example of a vaccine given by injectable route is JYNNEOS, which is administered by subcutaneous route in two doses (0.5 mL) 4 weeks apart.

Regional Insights

North America dominated the market with a revenue share of over 40.0% in 2022 due to the presence of a large number of leading players, coupled with various strategic initiatives undertaken by them. Moreover, the increase in disease prevalence and rising awareness among people regarding vaccination are expected to spur regional market expansion. In addition, favorable support from the government and higher R&D investments are anticipated to provide lucrative growth opportunities for the North American region.

Monkeypox Vaccine And Treatment Market Trends by Region

Asia Pacific is projected to witness the fastest growth over the forecast period. The increasing number of monkeypox infections and increasing R&D for developing prevention and therapeutic options are some of the primary factors driving the market. Increasing prevalence of infection in Asia Pacific countries such as Australia, Singapore, and India is expected to fuel the market growth.

Key Companies & Market Share Insights

Key players are adopting strategies such as new product development, mergers & acquisitions, and partnerships to increase their market share. For instance, in August 2022, Japan approved KM Biologics’ LC16 KMB vaccine for monkeypox disease. Some prominent players in the global monkeypox vaccine and treatment market include:

  • Bavarian Nordic

  • SIGA Technologies

  • Chimerix

  • EMERGENT

  • Gilead Sciences, Inc.

Monkeypox Vaccine And Treatment Market Report Scope

Report Attribute

Details

Market size value in 2023

USD 200.23 million

Revenue forecast in 2030

USD 184.79 million

Growth rate

CAGR of 10.16% from 2022 to 2030

Base year for estimation

2022

Historical data

2022 - 2030

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million and CAGR from 2022 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, gender, route of administration, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; India; China; Japan; Australia; South Korea; Brazil; Mexico; Argentina; Saudi Arabia; UAE; South Africa

Key companies profiled

Bavarian Noric; SIGA Technologies; Chimerix; EMERGENT; Gilead Sciences, Inc.

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

 

Global Monkeypox Vaccine And Treatment Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2030. For the purpose of this report, Grand View Research has segmented the global monkeypox vaccine and treatment market report on the basis of product, gender, route of administration, end-use, and region:

Global Monkeypox Vaccine And Treatment Market Segmentation

  • Product Outlook (Revenue, USD Million, 2022 - 2030)

    • Vaccine

      • JYNNEOS/ Imvanex

      • Smallpox Vaccine

      • Others           

    • Drugs

      • Tecovirimat

      • Brincidofovir

      • Cidofovir

      • Others

    • Vaccinia Immune Globulin (VIG)

  • Gender Outlook (Revenue, USD Million, 2022 - 2030)

    • Male

    • Female

    • Others

  • Route of Administration Outlook (Revenue, USD Million, 2022 - 2030)

    • Oral

    • Injectable

  • End-use Outlook (Revenue, USD Million, 2022 - 2030)

    • Hospitals

    • Specialty Clinics

    • Others

  • Regional Outlook (Revenue, USD Million, 2022 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

    • Asia Pacific

      • Japan

      • China

      • India

      • South Korea

      • Australia

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE 

Frequently Asked Questions About This Report

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.